Royal Bank of Canada’s Verrica Pharmaceuticals VRCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5K | Sell |
764
-201
| -21% | -$1.25K | ﹤0.01% | 6954 |
|
|
2026
Q1 | $5K | Buy |
965
+549
| +132% | +$3.52K | ﹤0.01% | 6446 |
|
|
2025
Q4 | $3K | Sell |
416
-793
| -66% | -$4.39K | ﹤0.01% | 6860 |
|
|
2025
Q3 | $5K | Buy |
1,209
+704
| +139% | +$4.25K | ﹤0.01% | 6718 |
|
|
2025
Q2 | $3K | Sell |
505
-136
| -21% | -$732 | ﹤0.01% | 6762 |
|
|
2025
Q1 | $2K | Buy |
641
+297
| +86% | +$1.92K | ﹤0.01% | 6600 |
|
|
2024
Q4 | $2K | Sell |
344
-2,235
| -87% | -$24.6K | ﹤0.01% | 6736 |
|
|
2024
Q3 | $37K | Buy |
2,579
+2,300
| +824% | +$104K | ﹤0.01% | 5843 |
|
|
2024
Q2 | $20K | Buy |
279
+31
| +13% | +$2.38K | ﹤0.01% | 6082 |
|
|
2024
Q1 | $15K | Sell |
248
-628
| -72% | -$34.7K | ﹤0.01% | 6045 |
|
|
2023
Q4 | $64K | Sell |
876
-78
| -8% | -$3.21K | ﹤0.01% | 5878 |
|
|
2023
Q3 | $37K | Sell |
954
-17
| -2% | -$864 | ﹤0.01% | 5936 |
|
|
2023
Q2 | $55K | Buy |
971
+547
| +129% | +$33.2K | ﹤0.01% | 5731 |
|
|
2023
Q1 | $27K | Buy |
424
+139
| +49% | +$8.41K | ﹤0.01% | 5918 |
|
|
2022
Q4 | $8K | Buy |
285
+1
| +0.4% | +$27 | ﹤0.01% | 6623 |
|
|
2022
Q3 | $8K | Sell |
284
-30,000
| -99% | -$1.03M | ﹤0.01% | 6556 |
|
|
2022
Q2 | $581K | Buy |
30,284
+29,964
| +9,364% | +$1.51M | ﹤0.01% | 3955 |
|
|
2022
Q1 | $26K | Sell |
320
-219
| -41% | -$18K | ﹤0.01% | 6471 |
|
|
2021
Q4 | $49K | Buy |
539
+267
| +98% | +$30.2K | ﹤0.01% | 6388 |
|
|
2021
Q3 | $35K | Buy |
272
+75
| +38% | +$8.41K | ﹤0.01% | 6372 |
|
|
2021
Q2 | $22K | Sell |
197
-11
| -5% | -$1.33K | ﹤0.01% | 6527 |
|
|
2021
Q1 | $31K | Buy |
208
+68
| +49% | +$9.41K | ﹤0.01% | 6187 |
|
|
2020
Q4 | $16K | Buy |
140
+32
| +30% | +$2.94K | ﹤0.01% | 6170 |
|
|
2020
Q3 | $8K | Sell |
108
-2
| -2% | -$164 | ﹤0.01% | 6015 |
|
|
2020
Q2 | $12K | Sell |
110
-37
| -25% | -$4.28K | ﹤0.01% | 5778 |
|
|
2020
Q1 | $16K | Sell |
147
-69
| -32% | -$9.08K | ﹤0.01% | 5642 |
|
|
2019
Q4 | $34K | Buy |
216
+109
| +102% | +$16.1K | ﹤0.01% | 5632 |
|
|
2019
Q3 | $16K | Hold |
107
| – | – | ﹤0.01% | 5607 |
|
|
2019
Q2 | $12K | Sell |
107
-5
| -4% | -$469 | ﹤0.01% | 5973 |
|
|
2019
Q1 | $12K | Buy |
112
+4
| +4% | +$461 | ﹤0.01% | 5910 |
|
|
2018
Q4 | $9K | Sell |
108
-21
| -16% | -$2.55K | ﹤0.01% | 5952 |
|
|
2018
Q3 | $21K | Buy |
129
+2
| +2% | +$342 | ﹤0.01% | 5661 |
|
|
2018
Q2 | $25K | Buy |
+127
| New | +$24.9K | ﹤0.01% | 5446 |
|
Other funds holding VRCA
CP
CC
AAA
VCIM
AC
BFM
Royal Bank of Canada's VRCA Position: Q2 2026 in Review
Royal Bank of Canada reduced its Verrica Pharmaceuticals (VRCA) stake by 21% in Q2 2026, selling an estimated $1.25K and leaving 764 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #6954.
Royal Bank of Canada first reported a position in VRCA in Q2 2018 and has held it in 33 quarters since. The position peaked at $581K in Q2 2022. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.
- Royal Bank of Canada held 764 shares of Verrica Pharmaceuticals worth $5K as of Q2 2026.
- Royal Bank of Canada sold 201 Verrica Pharmaceuticals shares in Q2 2026, an estimated $1.25K.
- Verrica Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6954 holding.
- Royal Bank of Canada first reported a position in Verrica Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- Royal Bank of Canada's Verrica Pharmaceuticals position peaked at $581K in Q2 2022.
- 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.